首页> 外文OA文献 >A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

【2h】

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

机译：肝癌患者与人表皮生长因子受体-2（HER2） - 阳性转移乳腺癌患者组合的阶段I试验Ganetespib与紫杉醇和曲妥珠单抗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Komal Jhaveri; Rui Wang; Eleonora Teplinsky; Sarat Chandarlapaty; David Solit; Karen Cadoo; James Speyer; Gabriella D’Andrea; Sylvia Adams; Sujata Patil; Sofia Haque; Tara O’Neill; Kent Friedman; Francisco J. Esteva; Clifford Hudis; Shanu Modi;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer [J] . Komal Jhaveri, Rui Wang, Eleonora Teplinsky, Breast Cancer Research . 2017,第1期

机译：ganetespib联合紫杉醇和曲妥珠单抗治疗人表皮生长因子受体2（HER2）阳性转移性乳腺癌的I期试验
2. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE [J] . Johnston Stephen R. D., Hegg Roberto, Im Seock-Ah, Journal of Clinical Oncology . 2018,第8期

机译：III期，双人表皮生长因子受体2（HER2）的随机研究与Lapatinib Plus Trastuzumab相结合，与Her2阳性激素受体阳性转移性乳腺癌的绝经后妇女中的芳香酶抑制剂组合：替代
3. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Nivolumab的II期与激素受体阳性，人体表皮生长因子受体-2负转移性乳腺癌患者的患者组合患者（WJOG11418B，NewFlame试验）
4. Combination of Novel HER2 Targeting Antibody 1A12 with Trastuzumab Shows Synergistic Antitumor Activity in HER2 Positive Gastric Cancer [C] . Kyu-Tae Kim, Jong-Seo Lee, Ki-Hyun Kim, PEGS . 2015

机译：具有曲妥珠单抗的新型HER2靶向抗体1a12的组合在HER2阳性胃癌中显示了协同抗肿瘤活性
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer [O] . Komal Jhaveri, Rui Wang, Eleonora Teplinsky, 2017

机译：ganetespib联合紫杉醇和曲妥珠单抗治疗人表皮生长因子受体2（HER2）阳性转移性乳腺癌的I期临床试验
7. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy [O] . José Baselga, Karen A. Gelmon, Shailendra Verma, 2010

机译：在先前的曲妥珠单抗治疗期间进展的人体表皮生长因子受体2阳性转移性乳腺癌患者中Pertuzumab和Trastuzumab的II期试验

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅